Talk:Multiple myeloma

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Medicine (Rated C-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follows the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
 C  This article has been rated as C-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
 
WikiProject Veterinary medicine (Rated Start-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Veterinary medicine, a collaborative effort to improve the coverage of Veterinary medicine on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
 Start  This article has been rated as Start-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
 


Contents

[edit] Can someone clarify the assessment of bone lesions used in staging, please?

The scheme as outlined here differs from the original, described in Durie and Salmon (1975), in which bone lesions were graded on a four point scale, namely: Normal bones (0); Osteoporosis (1); Lytic bone lesions (2); Extensive skeletal destruction and major fractures (3).

Stage I included normal bones (0) or solitary plasmacytoma, stage II by implication included osteoporosis (1) or lytic bone lesions (2), and stage III included scale point (3), now defined as 'Advanced lytic bone lesions' in the table describing the staging system.

Does anyone have a reference that supports the grading of bone lesions as laid out in the current Wikipedia article? I note that this scheme is that used by the CIBMTR, except for the inclusion of osteoporosis in stage I which the original scheme of Durie and Salmon include in stage II and which the CIBMTR ignore altogether.

As ever, there is nothing new under the Sun and this point has been raised elsewhere, although not answered as far as I know, before (see http://radiology.rsnajnls.org/cgi/reprint/234/1/313.pdf). However, the current scheme is not based on the Durie and Salmon PLUS staging system, in which lesions are determined using MRI and/or FDG PET, referred to in the Mulligan letter.

Any pointers would be appreciated. By the way, please tell me if this is not the right forum for raising this question and where is.Johnacle (talk) 00:46, 2 January 2008 (UTC)

I'm not sure how the grading of bone disease plugs into the full D&S system. JFW | T@lk 10:19, 28 March 2008 (UTC)

[edit] Rituximab

13-22% might respond to anti-CD20 monoclonal antibody: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2008.07024.x JFW | T@lk 07:10, 17 March 2008 (UTC)

doi:10.1182/blood-2007-10-121285 - numerous conditions seem to increase myeloma risk as a nonspecific trigger. JFW | T@lk 00:39, 25 March 2008 (UTC)
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2008.06997.x - PAD (Bortezomib, doxorubicin and dexamethasone) as first-line treatment does fairly well. JFW | T@lk 10:11, 28 March 2008 (UTC)

[edit] Bob & Vince

Kyle & Rajkumar about the history of myeloma. http://bloodjournal.hematologylibrary.org/cgi/content/full/111/6/2962 JFW | T@lk 05:18, 8 May 2008 (UTC)

[edit] heavily weighted towards a clinical perspective and treatment

I understand that many people coming to this page may be interested in the clinical evaluation of this disease, but I think it (the article) would benefit from additional information on the natural history. Surely there must also be a great deal of information available about (putative) etiology and biology of this disease that could at least be cited. DulcineadT (talk) 00:05, 11 March 2009 (UTC)

I agree. Please find a useful source. The article tries to address the common cytogenetic and immunohistochemical findings, as well as mutations involving IgH/IgL. We should certainly write about the bone microenvironment, as this is relevant with regards to the mechanism of action of thalidomide. JFW | T@lk 07:12, 11 March 2009 (UTC)

[edit] External link

I find http://www.myelomaforums.com/ not an external link we want to exclude. There is no formal guideline to discourage support groups but previous discussions on WT:MED have discouraged them. The person who added it is the site maintainer. --Steven Fruitsmaak (Reply) 07:47, 21 April 2009 (UTC)

Forums, discussion groups or other user-generated sites are usually poor sources of authoritative information. Obviously some are exemplary and well moderated, but others are the nidus of hype and untested treatments. This particular site has reasonably well-written content that more or less duplicates what this page is already telling. I think a broader discussion on WT:MEDMOS to generate some sort of general guidance would be very useful. JFW | T@lk 10:01, 21 April 2009 (UTC)

Guy's I really appreciate you at least taking the time to talk about it. My site does contain a lot of redundant information as do the other sites listed. However, each of us is truly trying to bring the best information to Myeloma patients. I may not have multi-million dollar grants or a PHD, but I can make a difference and give the Myeloma community a wonderful tool to help aid their fight. When people discuss their treatments they help others learn about the options available so they can consult their physicians. The physicians also use the forums as a tool to learn about patients and treatment options offered else where. I don't want to be rude, but flat out not telling people about my forums stops people from quickly finding valuable resources that have taken some patients years to find and time is very important when your fighting for your life. As a admin I respect what your doing and know your trying to keep wikipedia's image clean and have accurate information. I promise my site will be of value and a useful resource to everyone visiting wikipedia. Im 2 months in and patients have said things like "This is the best thing since color tv", "Where has this been all these years." and many many more praises. These comments tell me that my site is different and needed. I really need some friends to help me here since I dont have the million dollar budget. Please, please, please... Begging you! help me and the Myeloma community. 72.91.70.12 (talk) 03:11, 23 April 2009 (UTC)

Rather than simply reinserting your link, could you wait until a clear consensus has emerged? You may need to involve other contributors to weigh in over here. As it stands, there is a longstanding opposition here to any form of user-generated or support forum like links on Wikipedia pages. There are numerous other ways to reach the "myeloma community", for instance through Google ads or by Facebook groups. JFW | T@lk 21:47, 25 April 2009 (UTC)

The only clear consensus that will emerge out of this is how sad of a human being you are. YOUR opposition does nothing to help the Myeloma community. Your bad for the image of wikipedia and should be removed from power. 72.91.70.12 (talk) 04:20, 26 April 2009 (UTC)

Please avoid personal attacks and assume good faith. Being abusive will achieve absolutely nothing. If you expect us to carry your link, then at least have the courtesy to try and understand this website's workings. You have already succeeded at having the page locked from editing, and you are inches away from having your IP blocked. JFW | T@lk 07:22, 26 April 2009 (UTC)

Jeff we ready to unlock this section yet? Keep looking at www.myelomaforums.com and you will see that the sight is getting better and better and your making a mistake by not allowing my link. Also, it be nice if people could add content. 72.91.70.12 (talk) 11:34, 18 May 2009 (UTC)

[edit] RfC: Is myelomaforums.com link relevant for the links section of this article


[edit] Renal Failure

The section on renal failure here makes no mention of cast nephropathy, but my reading suggests it's far and away the most common cause of renal impairment in people with multiple myeloma. There doesn't really seem to be much if any mention of myeloma cast nephropathy at all on wiki, perhaps could do with inclusion? I'm not able to do it right now, but unless others have objections, or if it's already residing here under a different name, I might try and add in a bit of info at a later date. McPat (talk) 13:37, 9 July 2009 (UTC)

I've meant to spend some time on this article for a long time. Please include whatever you can find on cast nephropathy and other forms of myeloma kidney (there are several). JFW | T@lk 18:31, 9 July 2009 (UTC)

[edit] Lancet

doi:10.1016/S0140-6736(09)60221-X, 16 pages and 148 references. Might be useful. JFW | T@lk 00:43, 31 July 2009 (UTC)

Raab in Lancet; Seems to need paid subscription. - Rod57 (talk) 10:24, 10 January 2012 (UTC)

[edit] Incurable

I disagree with the removal from list of incurable diseases, as MM is still incurable. There really aren't remissions according to our oncologists, more "supressions". My husband is told "you're in great health, except you have cancer." - but as I know this is not citable, can someone look into the removal? Survival time is increasing, but it's still an incurable disease. It never is completely gone. (Someday...I'll never stop hoping) Trista (Triste Tierra - cannot log in at work) 24.176.191.234 (talk) 18:01, 17 July 2010 (UTC)

What list are you talking about? This article plainly says that it is considered incurable. Are you talking about some other page? WhatamIdoing (talk) 04:12, 18 July 2010 (UTC)
Sorry, I should have been more clear. Someone removed MM from the -category- of incurable diseases. About the same time some questionable information about survival began showing up. I'm a doof. Trista 24.176.191.234 (talk) 00:11, 21 July 2010 (UTC)
As far as I know, there's no such category. Category:Incurable diseases, at least, does not exist. WhatamIdoing (talk) 04:57, 21 July 2010 (UTC)

[edit] Kidney disease

doi:10.1182/blood-2010-03-258608 is a brand new high profile review that looks into myeloma-related kidney disease. It could be a useful scaffold for the relevant content. JFW | T@lk 08:27, 6 September 2010 (UTC)

[edit] Sources for improvement

This article is in a fairly good state, but it needs some updating in view of the many recent studies, and we need to drop a few primary research articles. I have already added Raab as a recent high-quality source.

  • 20462963 - the kidney paper mentioned above
  • 19541364 - Raab
  • 15031034 - Lancet review 2004 (Raab states that it is a good source for clinical data)

Depending a lot on how busy I will be the next few days, I will do some work here. JFW | T@lk 10:46, 6 September 2010 (UTC)

[edit] Research

Any objections to a short section on current research and experimental therapies in late stage clinical trials ? Maybe even a mention of Carfilzomib. Rod57 (talk) 13:02, 9 September 2010 (UTC)

There are so many agents, some of which may still die in late stages. I find it much more useful to discuss the various pathways that are being targeted, e.g. proteasome inhibition (as in bortezomib). What kind of source were you hoping to use for such as section? JFW | T@lk 09:41, 12 September 2010 (UTC)
No specific source but an anti-IL-6 CNTO 328 is in phase II. Rod57 (talk) 11:32, 16 November 2010 (UTC)
I would not want to raise false hopes and discuss agents that are not at least in phase III. JFW | T@lk 23:08, 16 November 2010 (UTC)

Current Advances in Non–Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma discusses mechanisms and some phase III trials eg of lenalidomide.

Current Advances in Novel Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma implies none are yet in phase III. - Rod57 (talk) 10:00, 10 January 2012 (UTC)

[edit] cause and heritability

Could someone write about the cause and heritability of this disease? My father has had Kahlers disease for about 4-5 years now. He is the youngest (73) of 9 brothers and sisters of whom 3 others had/have the disease as well. I always understood that the disease is not hereditary but that they may have encountered similar circumstances, poisonous substance at the farm where they all lived, for example. But when you write about the genetic alteration it makes me wonder. What causes the alteration? Thanks for this article, it has helped me to update my knowledge of the disease and the treatments. K. De Wit, Netherlands 80.127.208.155 (talk) 10:47, 20 October 2010 (UTC)

The genetic alterations in myeloma are usually acquired after birth rather than inherited. There is very limited data on environmental exposure as a cause for the disease. Online 'Mendelian Inheritance in Man' (OMIM) 254500 has some limited information about myeloma in family clusters. JFW | T@lk 19:06, 20 October 2010 (UTC)

[edit] "twice as common in blacks as in whites"?

The lead section claims that "The disease [...] is twice as common in blacks as it is in whites"[1].

For which definitions of "blacks" and "whites"?
--80.217.2.28 (talk) 14:52, 30 October 2011 (UTC)

Of course it's about blacks and whites in the United States (as Google tells us), so I put that into the article.
Is anything about this black–white difference stated in the source which is cited for the paragraph?
And what are the specific definitions of "black" or "African American" and "white American" used in the source, if any? --80.217.2.28 (talk) 14:01, 2 November 2011 (UTC)
Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export